IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

Core Viewpoint - IN8bio, Inc. announced promising long-term clinical data from its Phase 1 trial of INB-200 for glioblastoma multiforme (GBM), showing significant improvements in median progression-free survival (mPFS) compared to standard-of-care treatments [1][2][5]. Clinical Data Summary - The Phase 1 trial results indicate that repeated doses of INB-200 led to an mPFS of 16.1 months, which is an increase of 9.2 months or 132.6% over the historical mPFS of 6.9 months associated with the standard-of-care Stupp protocol [2][5]. - Notably, four patients (40%) who received repeated doses of INB-200 remain alive and progression-free for a median of over two years, with three of them returning to work [6][5]. - No dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed among the 13 patients treated with INB-200, with most adverse events being Grade 1-2 and consistent with typical chemotherapy side effects [3][5]. Comparison with Historical Data - The mPFS of 16.1 months for patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months associated with the standard-of-care Stupp protocol [5][6]. - The results demonstrate that 50% of patients receiving repeated doses remained progression-free for over 18 months, compared to 0% of patients who received a single dose [6]. Future Developments - IN8bio is also conducting a Phase 2 clinical trial of INB-400 for newly diagnosed GBM, which currently shows an mPFS of 10.8 months, with further updates expected in late 2025 [7]. - The company aims to leverage its gamma-delta T cell therapies to provide innovative treatment options for solid tumors like GBM, focusing on eliminating chemotherapy-resistant cancer cells [7].